Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 13/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30141501 | 0.90 | KDM4E (0.36) | KDM4EALDH1A1HPGDPLATLMNA | |
| SCHEMBL24906286 | 0.85 | KDM4E (0.34) | KDM4ERECQLCCR1LMNA | |
| SCHEMBL24906332 | 0.84 | LMNA (0.33) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL30951783 | 0.84 | LMNA (0.33) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL30951782 | 0.84 | LMNA (0.33) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL24906342 | 0.83 | LMNA (0.32) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL30975885 | 0.81 | LMNA (0.32) | KDM4EALDH1A1HPGDPLATLMNA | |
| SCHEMBL30975983 | 0.81 | LMNA (0.32) | KDM4EALDH1A1HPGDPLATLMNA | |
| SCHEMBL30976053 | 0.81 | LMNA (0.32) | KDM4EALDH1A1HPGDPLATLMNA | |
| SCHEMBL24758333 | 0.81 | POLB (0.41) | LMNAPOLBPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | KDM4E 2803/4885RECQL 3104/4885ALDH1A1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.